Tifcemalimab (JS004), a humanized monoclonal antibody targeting BTLA (B and T lymphocyte attenuation factor), inhibits the HVEM-BTLA interaction by binding to BTLA. This action prevents the BTLA-mediated inhibitory signaling pathway, making Tifcemalimab
* VAT and and shipping costs not included. Errors and price changes excepted